Rohit Amin, MD
Interventional Cardiology · Pensacola, FLNPI 1316139041
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $382,171 of the $560,308 with a category attached, or 68.2%. 53 manufacturers reported payments, led by Amgen at 43.9% of the total. Reporting peaked in 2019 at $155,603 and has fallen 76.2% since, to $37,092 in 2025. Among interventional cardiology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,299 payments — averaging $431.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$246K
- AstraZeneca$171K
- Inari Medical, Inc.$67K
- Abbott$23K
- Stryker$7K
- Bayer$7K
- plus $39K from 47 others
Across 158 payments — averaging $9276.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$474K
- Endotronix, Inc.$364K
- Amgen$226K
- Inari Medical, Inc.$158K
- American Regent$125K
- Cvrx, Inc.$39K
- plus $80K from 8 others
Across 5 payments — averaging $4284.70 each. An ownership or investment interest held by the physician or an immediate family member.
- Centerline Biomedical Inc.$21K
What the payments were for
- Consulting fees$35,7406%
- Speaking & faculty fees$382,17168%
- Travel & lodging$89,79516%
- Food & beverage$52,2819%
- Education$1780%
- Entertainment$1440%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$241,865
- BRILINTA$88,583
- FARXIGA$78,752
- FLOWTRIEVER CATHETER, S$71,580
- CT THROMBECTOMY SYSTEM KIT$70,268
- MitraClip$10,620
- Adempas$6,965
- AccuCinch$4,784
- Indigo System$4,442
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$3,325
- Impella$3,276
- AMPLATZER TALISMAN$3,150
- ENTRESTO$2,200
- Mitra Clip system$1,692
- TRICLIP$948
- CORDELLA PULOMONARY ARTERY PRESSURE SENSOR$821
- COREVALVE EVOLUT R$574
- Perclose ProStyle$502
- Paradise Ultrasound Renal Denervation System$487
- PARADISE RENAL DENERVATION SYSTEM$388
How this compares
$560,308 in reported general payments places this provider in the 95th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 18 | $457,647 |
| OpsumitMacitentan | 24 | $331,451 |
| EliquisApixaban | 286 | $269,369 |
| BrilintaTicagrelor | 235 | $204,622 |
| AdempasRiociguat | 11 | $153,350 |
| XareltoRivaroxaban | 163 | $148,498 |
| EntrestoSacubitril/Valsartan | 105 | $129,111 |
| FarxigaDapagliflozin Propanediol | 112 | $94,877 |
| Repatha SureclickEvolocumab | 68 | $75,994 |
| JardianceEmpagliflozin | 17 | $30,468 |
| Repatha PushtronexEvolocumab | 29 | $28,856 |
| ClopidogrelClopidogrel Bisulfate | 602 | $6,727 |
| Atorvastatin Calcium | 446 | $6,389 |
| Carvedilol | 543 | $4,494 |
| Ranolazine ErRanolazine | 53 | $4,325 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $914 | $789,09842 claims |
| AstraZenecaBrilinta, Farxiga | $171,160 | $299,499347 claims |
| PfizerEliquis | $459 | $269,369286 claims |
| BayerAdempas | $7,067 | $153,35011 claims |
| Johnson & JohnsonXarelto | $1,121 | $148,498163 claims |
| NovartisEntresto | $2,672 | $129,111105 claims |
| Boehringer IngelheimJardiance | $570 | $30,46817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Pensacola
- Arthur LeeGainesville$1.8M
- Santhosh MathewsBradenton$1.4M
- Siddharth WayangankarJacksonville$1.2M
- Patrick CambierTrinity$901K
- Zahid AminOrlando$635K
- Eduardo de MarchenaMiami$498K
- Dominick AngiolilloJacksonville$387K
- Miguel DiazHialeah$383K
- Douglas EbersoleLakeland$373K
- Amit SharmaMerritt Island$341K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.